The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin

Experimental Oncology

Volumn 30, Issue 1, 2008, Pages 52-55

  Berezhnaya, N M ^a   Vinnichuk, Yu D ^a   Belova, O B ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Doxorubicin; LAK; Melanoma; Resistance; Transplantable MC rhabdomyocarcoma

Indexed keywords

DOXORUBICIN; HEMATOXYLIN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CANCER CELL; CANCER GROWTH; CANCER MODEL; CANCER RESISTANCE; CELL STRUCTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION; DRUG CYTOTOXICITY; EXPLANT; FILTER; LYMPH NODE; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; RHABDOMYOSARCOMA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RHABDOMYOSARCOMA; TUMOR ESCAPE;

EID: 42049105782     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Koppold B, Sauer G, Buening H, et al. Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. J Cancer Res Clin Oncol 2006; 132: 787-94.
2. Berezhnaya NM, Kovalchuk EV, Spivak SI, et al. Antitumor action of lymphocytes in the dynamics of formation of the resistanse to doxorubicine in mice bearing transplantable MC-rhabdomyosarcoma. Exp Oncol 2002; 24: 292-5 (In Russian).
3. Berezhnaya NM, Vinnichuk YD, Konovalenko VF, et al. The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: a pilot study. Exp Oncol 2005; 27: 303-7.
4. Berezhnaya NM, Kovalchuk EV, Vinnichuk YD, et al. Experimental immunotherapy of mice with transplated MC-rhabdomiocarcoma resistant to doxorybicin. Exp Oncol 2004; 26: 63-7.
5. Eralp Y, Wang X, Wang JP. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004; 6: 275-83.
6. Rihova B, Strohalm J, Prausova J. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control Release 2003; 91: 1-16.
7. Frost P, Caliliw R, Belldegrun A, et al. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol 2003; 22: 431-7.
8. Ehrke MJ, Verstovsek S, Maccubbin DL, et al. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C56BL/6 mice. Int J Cancer 2000; 87: 101-9.
9. Zhu Q, Liu JY, Yang CM, et al. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol 2006; 18: 1071-7.
10. Law KS, Chen HC, Liao SK. Non-cytotoxic and sublethal paclitaxel treatment potentiated the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells. Anticancer Res 2007; 27: 841-50.
11. Bereznaya NM, Koval'chuk EV. LAK-phenomenon (cell phenotype, mechanism of action and conditions for its realization). Immunologiya 1995; 2: 12-6 (In Russian).
12. Fisk B, Ioannides CG. Increased sensitivity of adriamicin-selected tumor lines to CTL-mediated lysis results in enchanced drug sensitivity. Cancer Res 1998; 58: 4790-3.
13. Mizutani Y, Yoshida O, Miki T. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J Urol 1999; 162: 2171-5.
14. Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better (review). Int J Oncol 2001; 18: 417-24.